Cargando…

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Detalles Bibliográficos
Autores principales:	Xu, Ke, Park, Dongkyoo, Magis, Andrew T., Zhang, Jun, Zhou, Wei, Sica, Gabriel L., Ramalingam, Suresh S., Curran, Walter J., Deng, Xingming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238649/ https://www.ncbi.nlm.nih.gov/pubmed/32434536 http://dx.doi.org/10.1186/s12943-020-01214-5

Ejemplares similares

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Small Molecule Bax Agonists for Cancer Therapy
por: Xin, Meiguo, et al.
Publicado: (2014)

Discovery of Small Molecule Bak Activator for Lung Cancer Therapy
por: Park, Dongkyoo, et al.
Publicado: (2021)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
por: Wagner, Steve, et al.
Publicado: (2019)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Bery, Nicolas, et al.
Publicado: (2020)

Small-Molecule Inhibition of KRAS through Conformational Selection
por: Pagba, Cynthia V., et al.
Publicado: (2023)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
por: Bartolacci, Caterina, et al.
Publicado: (2022)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Distinct metabolic preference of atypical KRAS mutant
por: Cheong, Heesun
Publicado: (2020)

Correction: Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice
Publicado: (2018)

A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein
por: Carver, Joseph, et al.
Publicado: (2014)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

The small molecule BI-2852 induces a nonfunctional dimer of KRAS
por: Tran, Timothy H., et al.
Publicado: (2020)

Selective targeting of KRAS-Mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-Mutant cells
por: Hara, Toshifumi, et al.
Publicado: (2014)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

Correction: Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
Publicado: (2015)

Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
Publicado: (2015)

Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer
por: Singh, Kanchan, et al.
Publicado: (2021)

Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
por: Entrialgo‑Cadierno, Rodrigo, et al.
Publicado: (2023)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Acquired palbociclib resistance in KRAS-mutant lung cancer
por: Sherr, Charles J.
Publicado: (2018)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, Theodora, et al.
Publicado: (2017)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
por: Liu, Huiqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_re9l5tnahkq9hhdf085q52sc19